DUSP14

Summary

DUSP14 (dual specificity phosphatase 14, HGNC:17007) is a protein-coding gene on chromosome 17q12, encoding Dual specificity protein phosphatase 14 (O95147). Involved in the inactivation of MAP kinases.

Dual-specificity phosphatases (DUSPs) constitute a large heterogeneous subgroup of the type I cysteine-based protein-tyrosine phosphatase superfamily. DUSPs are characterized by their ability to dephosphorylate both tyrosine and serine/threonine residues. They have been implicated as major modulators of critical signaling pathways. DUSP14 contains the consensus DUSP C-terminal catalytic domain but lacks the N-terminal CH2 domain found in the MKP (mitogen-activated protein kinase phosphatase) class of DUSPs (see MIM 600714) (summary by Patterson et al., 2009 [PubMed 19228121]).

Source: NCBI Gene 11072 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 30 total
• Druggable target: yes
• MANE Select transcript: NM_007026

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17007
Approved symbol	DUSP14
Name	dual specificity phosphatase 14
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	MKP-L, MKP6
Ensembl gene	ENSG00000276023
Ensembl biotype	protein_coding
OMIM	606618
Entrez	11072

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 19 protein_coding

ENST00000613659, ENST00000614411, ENST00000617516, ENST00000908259, ENST00000908260, ENST00000908261, ENST00000908262, ENST00000908263, ENST00000908264, ENST00000908265, ENST00000908266, ENST00000919177, ENST00000919178, ENST00000919179, ENST00000919180, ENST00000919181, ENST00000919182, ENST00000949144, ENST00000949145

RefSeq mRNA: 1 — MANE Select: NM_007026 NM_007026

CCDS: CCDS11320

Canonical transcript exons

ENST00000614294 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 93.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.7301 / max 353.2049, expressed in 1786 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160463	28.2262	1782
160464	2.1179	676
160466	0.3091	98
160465	0.0769	26

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory segment of nasal mucosa	UBERON:0005386	93.66	gold quality
skin of leg	UBERON:0001511	92.61	gold quality
placenta	UBERON:0001987	92.36	gold quality
zone of skin	UBERON:0000014	91.93	gold quality
stromal cell of endometrium	CL:0002255	91.09	gold quality
skin of abdomen	UBERON:0001416	91.00	gold quality
nucleus accumbens	UBERON:0001882	89.14	gold quality
putamen	UBERON:0001874	88.60	gold quality
caudate nucleus	UBERON:0001873	88.40	gold quality
left lobe of thyroid gland	UBERON:0001120	88.39	gold quality
thyroid gland	UBERON:0002046	88.06	gold quality
superior frontal gyrus	UBERON:0002661	87.94	gold quality
prefrontal cortex	UBERON:0000451	87.92	gold quality
adrenal tissue	UBERON:0018303	87.52	gold quality
gall bladder	UBERON:0002110	87.39	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.28	gold quality
primary visual cortex	UBERON:0002436	87.14	gold quality
frontal cortex	UBERON:0001870	86.95	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	86.77	gold quality
right lobe of thyroid gland	UBERON:0001119	86.58	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.29	gold quality
cerebral cortex	UBERON:0000956	86.14	gold quality
anterior cingulate cortex	UBERON:0009835	85.93	gold quality
right adrenal gland	UBERON:0001233	85.92	gold quality
left adrenal gland cortex	UBERON:0035825	85.81	gold quality
right adrenal gland cortex	UBERON:0035827	85.74	gold quality
adenohypophysis	UBERON:0002196	85.65	gold quality
right frontal lobe	UBERON:0002810	85.63	gold quality
left adrenal gland	UBERON:0001234	85.42	gold quality
esophagus mucosa	UBERON:0002469	85.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.91

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR2C2

miRNA regulators (miRDB)

54 targeting DUSP14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-199A-5P	99.51	69.71	1107
HSA-MIR-199B-5P	99.51	69.74	1098
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-155-5P	99.35	70.16	1509
HSA-MIR-580-5P	99.28	70.94	1776

Literature-anchored findings (GeneRIF, showing 10)

• Activation of ATM by radiation down-regulates phospho-ERK1/2 and its downstream signaling via increased expression of mitogen-activated protein kinase phosphatase MKP-1. (PMID:17178844)
• The binding of Lipomannan to TLR2 triggers MAPK activation, followed by an up-regulation of MKP-1 expression, which in turn may act as a negative regulator of MAPK activation. (PMID:18201568)
• The overproduction, purification and crystal structure at 1.88 A resolution of human dual-specificity phosphatase 14, DUSP14 (MKP6), are reported. (PMID:19770498)
• DUSP14 may be a susceptibility gene for pulmonary tuberculosis. (PMID:22233810)
• findings suggest that DUSP14 negatively regulates TNF- or IL-1-induced NF-kappaB activation by dephosphorylating TAK1 at Thr-187 (PMID:23229544)
• these findings reveal a novel mechanism by which TRAF2 mediates Lys63-linked ubiquitination of DUSP14, leading to DUSP14 activation in T cells (PMID:26521044)
• levels significantly decreased in failing hearts (PMID:26891723)
• The AA genotype was associated with protection against active TB. Among disease-free individuals, T-helper type-1 related genes, IFNGR2 and STAT1 mRNA levels significantly increased as the number of A alleles of rs1051838 increased. (PMID:26938665)
• Hepatocyte DUSP14 is required for maintaining hepatic metabolic homeostasis and for suppressing inflammation, a novel function that relies on constraining TAK1 hyperactivation (PMID:29077210)
• Bioinformatic studies showed that these two miRNAs target PTEN and DUSP14 tumor suppressor genes. Quantitative Real-time PCR confirmed the overexpression of the miRNAs and downregulation of their targets. Luciferase assay confirmed that the miRNAs target PTEN and DUSP14. (PMID:30335891)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Dusp14	ENSMUSG00000018648
rattus_norvegicus	Dusp14	ENSRNOG00000030091
rattus_norvegicus	Dusp14l1	ENSRNOG00000079426

Paralogs (31): DUSP13B (ENSG00000079393), DUSP12 (ENSG00000081721), SSH1 (ENSG00000084112), DUSP3 (ENSG00000108861), PTPMT1 (ENSG00000110536), DUSP16 (ENSG00000111266), EPM2A (ENSG00000112425), DUSP22 (ENSG00000112679), DUSP1 (ENSG00000120129), DUSP4 (ENSG00000120875), STYXL1 (ENSG00000127952), DUSP9 (ENSG00000130829), DUSP26 (ENSG00000133878), DUSP5 (ENSG00000138166), DUSP6 (ENSG00000139318), SSH2 (ENSG00000141298), DUSP10 (ENSG00000143507), DUSP15 (ENSG00000149599), DUSP2 (ENSG00000158050), KASH5 (ENSG00000161609), DUSP19 (ENSG00000162999), DUSP7 (ENSG00000164086), DUSP18 (ENSG00000167065), SSH3 (ENSG00000172830), DUSP8 (ENSG00000184545), DUSP28 (ENSG00000188542), DUSP29 (ENSG00000188716), DUSP21 (ENSG00000189037), STYX (ENSG00000198252), STYXL2 (ENSG00000198842), DUSP13A (ENSG00000293543)

Protein

Protein identifiers

Dual specificity protein phosphatase 14 — O95147 (reviewed: O95147)

Alternative names: MKP-1-like protein tyrosine phosphatase, Mitogen-activated protein kinase phosphatase 6

All UniProt accessions (2): O95147, Q6FI36

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the inactivation of MAP kinases. Dephosphorylates ERK, JNK and p38 MAP-kinases. Plays a negative role in TCR signaling by dephosphorylating MAP3K7 adapter TAB1 leading to its inactivation.

Subunit / interactions. Interacts with CD28.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class dual specificity subfamily.

RefSeq proteins (1): NP_008957* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000340	Dual-sp_phosphatase_cat-dom	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR016130	Tyr_Pase_AS	Active_site
IPR020420	Atypical_DUSP_subfamB	Family
IPR020422	TYR_PHOSPHATASE_DUAL_dom	Domain
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR052103	Dual_spec_Phospatases	Family

Pfam: PF00782

Catalyzed reactions (Rhea), 3 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)
• O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + phosphate (RHEA:20629)
• O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + phosphate (RHEA:47004)

UniProt features (20 total): strand 9, helix 8, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2WGP	X-RAY DIFFRACTION	1.88

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95147-F1	89.31	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 111 (phosphocysteine intermediate)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 196 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, AP1_01, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, ENK_UV_RESPONSE_KERATINOCYTE_UP, KEGG_MAPK_SIGNALING_PATHWAY, SP3_Q3, HUMMERICH_SKIN_CANCER_PROGRESSION_DN, WEI_MYCN_TARGETS_WITH_E_BOX, AP1_Q4_01, ONKEN_UVEAL_MELANOMA_UP, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, FOSTER_TOLERANT_MACROPHAGE_UP, NF1_Q6_01, SASSON_RESPONSE_TO_FORSKOLIN_DN

GO Biological Process (2): protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311)

GO Molecular Function (7): RNA binding (GO:0003723), protein serine/threonine phosphatase activity (GO:0004722), protein tyrosine phosphatase activity (GO:0004725), MAP kinase tyrosine/serine/threonine phosphatase activity (GO:0017017), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphoprotein phosphatase activity	2
dephosphorylation	1
protein modification process	1
phosphate-containing compound metabolic process	1
nucleic acid binding	1
protein tyrosine/serine/threonine phosphatase activity	1
MAP kinase phosphatase activity	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DUSP14	C17orf78	Q8N4C9	599
DUSP14	CD28	P10747	580
DUSP14	SYNRG	Q9UMZ2	556
DUSP14	TADA2A	O75478	538
DUSP14	MRM1	Q6IN84	500
DUSP14	MAPK14	Q16539	482
DUSP14	DDX52	Q9Y2R4	476
DUSP14	PIGW	Q7Z7B1	467
DUSP14	ZNHIT3	Q15649	463
DUSP14	UBB	P02248	450
DUSP14	GGNBP2	Q9H3C7	450
DUSP14	DUSP11	O75319	388
DUSP14	MYO19	Q96H55	378
DUSP14	TAB1	Q15750	377
DUSP14	FBXO16	Q8IX29	375

IntAct

160 interactions, top by confidence:

A	B	Type	Score
OAZ3	AZIN1	psi-mi:“MI:0914”(association)	0.800
SMARCD1	ARID1A	psi-mi:“MI:0914”(association)	0.790
KIF3A	KIF3C	psi-mi:“MI:0914”(association)	0.730
ANXA9	PPL	psi-mi:“MI:0914”(association)	0.660
RAB11B	SH3BP5	psi-mi:“MI:0914”(association)	0.640
CAPZA2	CNOT1	psi-mi:“MI:0914”(association)	0.640
DUSP14	CBY2	psi-mi:“MI:0915”(physical association)	0.560
CBY2	DUSP14	psi-mi:“MI:0915”(physical association)	0.560
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
HEATR1	SLC27A2	psi-mi:“MI:0914”(association)	0.530
PMM1	PMM2	psi-mi:“MI:0914”(association)	0.530
CCDC51	TGM5	psi-mi:“MI:0914”(association)	0.530
GDF5	SERPINB7	psi-mi:“MI:0914”(association)	0.530
CPLX3	CIAO1	psi-mi:“MI:0914”(association)	0.530
B3GALNT1	DUSP14	psi-mi:“MI:0914”(association)	0.530
CFAP210	DUSP14	psi-mi:“MI:0914”(association)	0.530
SYT16	DUSP14	psi-mi:“MI:0914”(association)	0.530
LPCAT4	DUSP14	psi-mi:“MI:0914”(association)	0.530
LACC1	DUSP14	psi-mi:“MI:0914”(association)	0.530
NSMAF	DUSP14	psi-mi:“MI:0914”(association)	0.530
OTULIN	DUSP14	psi-mi:“MI:0914”(association)	0.530
MRPL38	DUSP14	psi-mi:“MI:0914”(association)	0.530
RHOBTB2	DUSP14	psi-mi:“MI:0914”(association)	0.530
OR51E2	DUSP14	psi-mi:“MI:0914”(association)	0.530
FBXL4	DUSP14	psi-mi:“MI:0914”(association)	0.530
ANKH	FAM234B	psi-mi:“MI:0914”(association)	0.530

BioGRID (237): SPERT (Two-hybrid), DUSP14 (Affinity Capture-RNA), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS), DUSP14 (Affinity Capture-MS)

ESM2 similar proteins: A4D256, A4IHU7, O14830, O35239, O35385, O95147, P0C591, P0C592, P0C593, P0C594, P0C595, P0C596, P0C597, P0C598, P0C599, P0C5A0, P0C5A1, P0C5A2, P43378, P51452, Q16828, Q17QM8, Q29RA3, Q2KJ36, Q4KL92, Q4RQD3, Q566R7, Q5RD73, Q5XHB2, Q641Z2, Q64346, Q68J44, Q6AXW7, Q6GQJ8, Q86BN8, Q8BK84, Q8K4T5, Q8WTR2, Q8WUK0, Q90W58

Diamond homologs: A4IHU7, F1QWM2, O09112, O13632, O55737, O95147, P0C591, P0C592, P0C593, P0C594, P0C595, P0C596, P0C597, P0C598, P0C599, P0C5A0, P0C5A1, P0C5A2, P28562, P28563, P51452, Q05922, Q13115, Q13202, Q148W8, Q16828, Q16829, Q17QJ3, Q17QM8, Q1LWL2, Q29RA3, Q2KJ36, Q39491, Q4KL92, Q4RQD3, Q4V7N3, Q54T76, Q54Y32, Q556Y8, Q55BI8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
TANK	“up-regulates activity”	DUSP14	ubiquitination
DUSP14	“down-regulates activity”	TAB1	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 175 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor protein tyrosine kinase signaling pathway	10	10.5×	4e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

568 predictions. Top by Δscore:

Variant	Effect	Δscore
17:37489958:GGTA:G	donor_loss	1.0000
17:37489959:GTAG:G	donor_loss	1.0000
17:37489960:T:A	donor_loss	1.0000
17:37510761:GGAA:G	donor_gain	1.0000
17:37510762:G:GT	donor_gain	1.0000
17:37510762:GAA:G	donor_gain	1.0000
17:37510765:G:GG	donor_gain	1.0000
17:37512178:CAG:C	acceptor_loss	1.0000
17:37512179:A:AG	acceptor_gain	1.0000
17:37512180:G:GT	acceptor_gain	1.0000
17:37512180:GGA:G	acceptor_gain	1.0000
17:37512180:GGAA:G	acceptor_gain	1.0000
17:37489913:G:GT	donor_gain	0.9900
17:37489955:GCCG:G	donor_gain	0.9900
17:37489959:G:GG	donor_gain	0.9900
17:37510673:GCA:G	acceptor_loss	0.9900
17:37510675:A:AC	acceptor_loss	0.9900
17:37510675:A:AG	acceptor_gain	0.9900
17:37510676:G:GG	acceptor_gain	0.9900
17:37510676:G:GT	acceptor_loss	0.9900
17:37510676:GATTT:G	acceptor_gain	0.9900
17:37510760:AGGAA:A	donor_gain	0.9900
17:37510761:GGAAG:G	donor_gain	0.9900
17:37510763:AA:A	donor_gain	0.9900
17:37510763:AAG:A	donor_loss	0.9900
17:37510764:AG:A	donor_loss	0.9900
17:37510765:GTG:G	donor_loss	0.9900
17:37510766:T:A	donor_loss	0.9900
17:37510767:GA:G	donor_loss	0.9900
17:37510768:AG:A	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000213439 (17:37508664 G>A), RS1000255279 (17:37507747 C>G), RS1000268801 (17:37501971 T>C), RS1000324181 (17:37502322 C>T), RS1000465719 (17:37496128 C>T), RS1000473910 (17:37496365 G>A), RS1000630454 (17:37490702 T>G), RS1000672338 (17:37490266 T>A,C), RS1000921513 (17:37513186 T>G), RS1001041652 (17:37490160 C>CA), RS1001092120 (17:37506985 G>A), RS1001261177 (17:37506415 G>A), RS1001347490 (17:37494896 C>G), RS1001453078 (17:37495062 G>A), RS1001633646 (17:37488755 C>T)

Disease associations

OMIM: gene MIM:606618 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001941_16	Ovarian cancer	8.000000e-10
GCST004603_181	Platelet count	2.000000e-10
GCST004607_74	Plateletcrit	1.000000e-11
GCST004625_241	Monocyte count	5.000000e-10
GCST90002383_66	Hematocrit	5.000000e-11
GCST90002384_410	Hemoglobin	1.000000e-09
GCST90002393_518	Monocyte count	8.000000e-30
GCST90002402_451	Platelet count	1.000000e-17
GCST90002403_357	Red blood cell count	2.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007985	platelet crit
EFO:0005091	monocyte count
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0004305	erythrocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1764941 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	5
Aflatoxin B1	increases methylation, affects expression, decreases methylation, increases expression	5
Cisplatin	decreases expression, affects cotreatment, increases expression	4
sodium arsenite	decreases reaction, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
bisphenol A	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
deguelin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
nutlin 3	affects cotreatment, increases expression	1
thifluzamide	increases expression	1
abrine	increases expression	1
pyrachlostrobin	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Sunitinib	increases expression	1
Vorinostat	increases expression	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Adenine	decreases expression	1
Antimycin A	increases expression	1
Arsenic	affects methylation	1
Camptothecin	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1767973	Binding	Inhibition of human DUSP14	Utilization of nitrophenylphosphates and oxime-based ligation for the development of nanomolar affinity inhibitors of the Yersinia pestis outer protein H (YopH) phosphatase. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.